Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices
Based on the MONET results, the lower cost of DRV/r monotherapy versus triple therapy in the UK would allow more patients to be treated for fixed budgets, while maintaining HIV RNA suppression at >50 copies/mL. If all patients meeting the inclusion criteria of the MONET trial in the UK were switched to DRV/r monotherapy, there is the potential to save up to £60 million in antiretroviral drug costs from the UK NHS budget. </AbstractSection> Copyright Adis Data Information BV 2011
Year of publication: |
2011
|
---|---|
Authors: | Gazzard, Brian ; Hill, Andrew ; Anceau, Anne |
Published in: |
Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 9.2011, 4, p. 217-223
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices
Gazzard, Brian, (2011)
-
Pasquau, Juan, (2012)
-
Pasquau, Juan, (2012)
- More ...